Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

NCT05354362 is registered in ClinicalTrials.gov with Antengene Corporation as lead sponsor.

NCT NCT05354362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05354362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Lead sponsor
Antengene Corporation
Phase
Phase 1
Overall status
Terminated
Start date
March 2, 2022
Completion date
February 8, 2023
Enrollment
7 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory diffuse large b-cell lymphoma